Gene Therapy With URO-902 (pVAX/ <i>hSlo</i> ) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a Trial
In this phase 2a trial, treatment with URO-902 was associated with improvements vs placebo in efficacy and patient-reported outcomes and was safe and well tolerated.
Authors
- Ekene Enemchukwu (ORCID: https://orcid.org/0000-0001-6224-6207)
- Susan Kalota
- Sijian Ge
- Salim Mujais
- Hanh Badger
- Kenneth M. Peters (ORCID: https://orcid.org/0000-0001-9020-598X)
- Lu Jingmei
- Kaiser J. Robertson
Institutions
- Oakland University (US)
- Arizona Pain Specialists (US)
- Sumitomo Dainippon Pharma (United States) (US)
- Chesapeake Urology Associates (US)
- Stanford University (US)
Publication Details
- Journal
- The Journal of Urology
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1097/ju.0000000000004373
- Citations
- 4
- Primary Topic
- Tissue Engineering and Regenerative Medicine
- Type
- article
- Field-Weighted Citation Impact
- 8.03
Funders
- Boston Scientific Corporation